CAR T cells have been very successful therapies for people with blood cancers who have not responded to other treatments. But now the FDA is concerned that the cellular therapy might be linked to the ...
A large study by researchers at Stanford Medicine has found that the risk of secondary blood cancers after CAR-T cell therapy — a cell-based cancer treatment that exploded on the scene in 2017 as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results